Theravance BiopharmaTBPH
TBPH
About: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Employees: 97
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
2% more funds holding
Funds holding: 128 [Q4 2024] → 131 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
0.54% less ownership
Funds ownership: 91.29% [Q4 2024] → 90.75% (-0.54%) [Q1 2025]
5% less capital invested
Capital invested by funds: $422M [Q4 2024] → $401M (-$21.5M) [Q1 2025]
23% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 47
63% less call options, than puts
Call options by funds: $6K | Put options by funds: $16K
Research analyst outlook
We haven’t received any recent analyst ratings for TBPH.
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
Neutral
PRNewsWire
1 week ago
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022 , and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion First outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value ; Board remains committed to returning excess capital to shareholders DUBLIN , June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("Trelegy") to GSK (NYSE: GSK) for $225 million in cash. "Through this agreement with GSK to monetize our outer-year Trelegy royalties, we are translating our long-standing confidence in Trelegy's sustained success into immediate value for Theravance Biopharma shareholders," said Rick E Winningham, CEO of Theravance Biopharma.
Neutral
PRNewsWire
1 month ago
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
Neutral
Seeking Alpha
1 month ago
Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial officer Aine Miller - Head-Development Conference Call Participants Marc Frahm - TD Cowen Operator Hello, ladies and gentlemen. Good afternoon.
Neutral
Zacks Investment Research
1 month ago
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Neutral
PRNewsWire
1 month ago
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts. A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (NCT03829657), an international phase 3, placebo-controlled, double-blind, randomized withdrawal trial, designed to demonstrate clinical worsening in those assigned to placebo.
Negative
Zacks Investment Research
1 month ago
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.
Neutral
PRNewsWire
1 month ago
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 2024 1 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 2024 2 CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summer Quarter-end cash balance of $131 million, with no debt Reaffirming all financial guidance metrics DUBLIN , May 8, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2025. "As we begin the year, we remain focused on delivering against our operational priorities for YUPELRI and ampreloxetine," said Rick E Winningham, CEO of Theravance Biopharma.
Neutral
PRNewsWire
1 month ago
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Neutral
PRNewsWire
1 month ago
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day.
Charts implemented using Lightweight Charts™